Skip to main content

Table 4 SIR for subsequent ischemic stroke of patients with IMD

From: Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

 

Follow-up interval (years)

 

<1

1-5

5-10

> = 10

All

Immune-mediated diseases

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

Addison´s disease

14

2.71

1.48

4.56

28

1.17

0.78

1.69

30

1.90

1.28

2.72

11

0.97

0.48

1.74

83

1.48

1.18

1.83

Amyotrophic lateral sclerosis

7

0.53

0.21

1.10

16

1.52

0.87

2.47

7

1.77

0.70

3.67

2

1.15

0.11

4.23

32

1.09

0.74

1.54

Ankylosing spondylitis

8

1.62

0.69

3.21

44

1.55

1.13

2.08

24

0.98

0.63

1.46

35

1.08

0.75

1.50

111

1.23

1.01

1.48

Autoimmune hemolytic anemia

4

1.45

0.38

3.75

12

1.00

0.51

1.75

19

2.51

1.51

3.93

5

1.23

0.39

2.90

40

1.51

1.08

2.06

Behcet´s disease

1

4.00

0.00

22.93

1

0.65

0.00

3.70

0

   

1

1.43

0.00

8.19

3

0.78

0.15

2.29

Celiac disease

9

2.17

0.99

4.14

29

1.28

0.86

1.84

21

1.17

0.72

1.78

26

1.47

0.96

2.15

85

1.36

1.09

1.68

Chorea minor

0

   

1

2.27

0.00

13.03

0

   

0

   

1

1.11

0.00

6.37

Crohn disease

49

2.15

1.59

2.84

160

1.33

1.13

1.55

103

1.11

0.91

1.35

97

1.15

0.93

1.40

409

1.28

1.16

1.41

Diabetes mellitus type I

1

6.25

0.00

35.83

2

0.45

0.04

1.65

5

2.75

0.87

6.46

17

5.00

2.91

8.02

25

2.54

1.64

3.76

Discoid lupus erythematosus

3

4.23

0.80

12.51

3

0.99

0.19

2.92

1

0.47

0.00

2.70

3

1.55

0.29

4.60

10

1.28

0.61

2.37

Grave´s disease

101

2.15

1.76

2.62

402

1.39

1.26

1.53

348

1.36

1.22

1.51

276

1.27

1.12

1.43

1127

1.39

1.31

1.48

Hashimoto´s thyroiditis

77

2.99

2.36

3.74

211

1.73

1.50

1.98

115

1.39

1.14

1.67

82

1.28

1.02

1.59

485

1.64

1.50

1.80

Immune thrombocytopenic purpura

16

2.35

1.34

3.83

55

1.77

1.33

2.30

19

0.94

0.57

1.48

14

1.20

0.65

2.01

104

1.49

1.22

1.81

Localized scleroderma

2

1.28

0.12

4.71

13

1.25

0.66

2.14

18

1.72

1.01

2.72

11

1.04

0.51

1.86

44

1.33

0.97

1.79

Lupoid hepatitis

3

4.48

0.84

13.25

4

1.98

0.52

5.12

0

   

0

   

7

2.10

0.83

4.36

Multiple sclerosis

40

3.05

2.18

4.15

73

1.09

0.85

1.37

55

1.11

0.83

1.44

35

0.95

0.66

1.32

203

1.22

1.06

1.40

Myasthenia gravis

6

1.01

0.36

2.21

38

1.36

0.96

1.87

23

1.20

0.76

1.80

13

1.08

0.57

1.85

80

1.23

0.97

1.53

Pernicious anemia

25

1.56

1.01

2.31

138

1.49

1.25

1.76

89

1.23

0.99

1.52

74

1.44

1.13

1.80

326

1.40

1.25

1.56

Polyarteritis nodosa

5

1.23

0.39

2.89

20

1.30

0.79

2.02

11

1.05

0.52

1.88

10

1.13

0.54

2.08

46

1.19

0.87

1.58

Polymyalgia rheumatica

165

1.76

1.50

2.05

761

1.50

1.39

1.61

529

1.54

1.41

1.68

322

1.53

1.37

1.71

1777

1.54

1.47

1.61

Polymyositis/ dermatomyositis

10

3.46

1.65

6.39

13

1.19

0.63

2.03

6

1.07

0.38

2.34

5

1.73

0.55

4.07

34

1.52

1.05

2.13

Primary biliary cirrhosis

4

1.54

0.40

3.98

11

1.45

0.72

2.60

4

0.91

0.24

2.35

1

2.17

0.00

12.46

20

1.33

0.81

2.05

Psoriasis

44

1.92

1.39

2.58

217

1.65

1.44

1.89

163

1.53

1.30

1.78

144

1.41

1.19

1.66

568

1.56

1.44

1.70

Reiter´s disease

0

   

5

2.02

0.64

4.76

6

2.47

0.89

5.41

2

0.56

0.05

2.07

13

1.47

0.78

2.52

Rheumatic fever

5

3.91

1.23

9.19

10

1.66

0.79

3.06

14

3.04

1.65

5.11

7

1.81

0.72

3.75

36

2.28

1.59

3.16

Rheumatoid arthritis

345

2.08

1.86

2.31

1266

1.66

1.57

1.75

663

1.45

1.34

1.56

326

1.30

1.16

1.45

2600

1.59

1.53

1.65

Sarcoidosis

9

0.97

0.44

1.85

70

1.43

1.12

1.81

51

1.12

0.83

1.47

56

1.08

0.81

1.40

186

1.19

1.03

1.38

Sjögren´s syndrome

10

2.57

1.22

4.75

28

1.38

0.92

1.99

15

0.96

0.54

1.59

15

1.26

0.70

2.08

68

1.31

1.02

1.67

Systemic lupus erythematosus

19

2.21

1.33

3.46

88

2.33

1.87

2.87

54

1.92

1.44

2.51

30

1.26

0.85

1.80

191

1.94

1.68

2.24

Systemic sclerosis

11

1.90

0.94

3.41

28

1.22

0.81

1.77

11

1.19

0.59

2.14

2

0.39

0.04

1.43

52

1.21

0.90

1.58

Ulcerative colitis

71

2.15

1.68

2.71

231

1.27

1.11

1.45

162

1.09

0.92

1.27

146

1.05

0.89

1.24

610

1.21

1.12

1.31

Wegener´s granulomatosis

11

1.66

0.82

2.98

12

0.47

0.24

0.83

26

1.54

1.00

2.25

12

1.69

0.87

2.96

61

1.09

0.83

1.40

All

1075

2.02

1.90

2.14

3990

1.50

1.46

1.55

2592

1.38

1.33

1.43

1780

1.29

1.23

1.35

9437

1.46

1.43

1.49

  1. O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
  2. Bold type: 95% CI does not include 1.00.
  3. Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.